{"ticker": {"uuid": "c797b78b-4fee-4542-836b-4cb097d61c43", "symbol": "CELC", "name": "Celcuity LLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Celcuity Inc. (NASDAQ: CELC) on behalf of investors. The investigation follows a significant drop in Celcuity's stock price after the company announced U.S. Food and Drug Administration approval for its brea", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-celcuity-inc---celc-302828050.html", "source_name": "PR Newswire", "published_at": "2026-07-16T23:40:05", "published_display": "16 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPa0FVQmRoemh4cU9wNlpwZEhMbUx6YnVVaGZ5eGRsVG10TEtNM1o2Q1UyWElxTjhxelBPU01tOWcwRHZ1QmNjclI2bG0xSnhXajNFUWJ2ODVYb3ZCTGtRc0h6U2cyU1pyZUNHSzJQbEhjZTZfWXFKdlZja3FKdVJmT19jcXdEWVhvNHduVWhqNkhTU3JSOFJDM0NwdXZSVllzeFpHVVk5VHBCczRDVEdCaFNJdVpoRldxWl9RT0tDZTQ1dVk?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T22:27:29+00:00", "published_display": "16 Jul 2026 22:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Celcuity LLC For: 16 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxORFE4TmJrY01XZ2g5QmMyRlJEZ0o1anNyMGdTb053LTVSMDcyc3VSRl9LT0h3YnptRWYxZFNkQUJOSzhQOTYwMUxWR0pPek9QZzFaQXdYeV9sa2MyMnZFZVFtRmhaaFFZWmJ0M2hQcmdVWjNoejhmT09EUFotMHdKYVF5Mjg5eEJGc3F4aEFfUUdnaXJTTG5N?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-16T21:52:15+00:00", "published_display": "16 Jul 2026 21:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $155 to $178", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbU42UFNoR1JnWXRYVFdpUzZ2N3VBdktlS25iMVNOX3ItalpsZ2dDUXZIaWd1UVJzVElyT3NoRW1WYnRnUUJ5T0gwWTNwWS1VZE0wMjJwSFVlLXFlNy1yTmhNVlVKNFFTcG1velBvU1prc0ZnVm5TOUxBYnkzajNzbmlMdDlCYmltazFTUjllTFVXUlVTWXhNVA?oc=5", "source_name": "Moomoo", "published_at": "2026-07-16T13:08:27+00:00", "published_display": "16 Jul 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations", "summary": "Celcuity Inc. secured early FDA approval for REVTORPYK (gedatolisib) for HR+/HER2- breast cancer, signaling a potential multi-billion dollar market opportunity. The drug, a first-in-class pan-PI3K/mTOR inhibitor, demonstrated superior efficacy and a favorable safety profile compa", "url": "https://www.kavout.com/market-lens/celcuity-s-revtorpyk-approval-a-multi-billion-dollar-breakthrough-despite-high-expectations", "source_name": "Kavout | AI", "published_at": "2026-07-16T10:13:17", "published_display": "16 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity (CELC) Experiences Significant Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNcFB1ZnJvQk1zTml6cGt1d0RFYTJzZmRzcjJ3QTcyYmRNR1ZZanJkNmV4dkJEZ2N3VXRHYzNTMTlXcmRZMFhHWElqdFZJY1FidV8ydUktZWlUaDhjWTY0MjV6VlBMWmxqR1RqenYwRnZReXlqWWZiR05XY3NNYkY4ZWZCMEJ3QTd6SjVLMW1DVHZDdDNKYllMYWo3ZE9DZGNhS09DNnhLTG12OGZ6OVdJc2pDUWUtZmhsZk1RYXo2bnJlQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T03:02:52+00:00", "published_display": "16 Jul 2026 03:02", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026 (CELC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOc0xTNFZKbTN1Uzlab3l0MmJIZ2diWE1pUWRNZ1ZJT1VGWUd3MG1tRFFYOE1leHhzUG1ZbUFPNy1pVnhpOE0yN0RmTElKNnVkNWlNR2w4bEtuLWxERnB6em1tV2dnRXJlMFlMTTktYi1lSkk2VlJYNWFHX1FFdHJmam1oMzVkRC1pcW1IVUx5WkdmZDlod21aMi1zWmlobDhrbFJIOERCOUo4U0tIR0hSOGpfQU1EZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T17:45:24+00:00", "published_display": "15 Jul 2026 17:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity gains FDA approval for closely watched breast cancer drug", "summary": "Celcuity received FDA approval for its breast cancer drug, Revtorpyk, for use in specific combinations for advanced ER-positive, HER2-negative breast cancer patients without a PIK3CA mutation. Despite the approval, Celcuity's shares fell by nearly 20% due to a delayed launch time", "url": "https://www.biopharmadive.com/news/celcuity-fda-approve-revtorpyk-breast-cancer/825280/", "source_name": "BioPharma Dive", "published_at": "2026-07-15T16:10:35", "published_display": "15 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity\u2019s Revtorpyk wins FDA nod in breast cancer", "summary": "Celcuity Inc. received FDA approval for Revtorpyk (gedatolisib) for a subset of breast cancer patients, marking the company's first commercial product and a new treatment option. Despite this positive news, investor excitement was dampened by an unanticipated launch delay, causin", "url": "https://www.bioworld.com/articles/732608-celcuitys-revtorpyk-wins-fda-nod-in-breast-cancer", "source_name": "BioWorld News", "published_at": "2026-07-15T16:10:35", "published_display": "15 Jul 2026 16:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Slides as Investors Appear to Take Profits After FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbU9KM0FHTWx4SE5JWmtzTkZHa29vbDZKLXQ3SUFyWTVRLVZwZGhKaERqeVE1MXhtSVpIRkRtZ25xaEd6ZVVPNlhRbDNaRkgtOFJKTnNLOEY3dzhjelBiR0NtWXpsbGpaUW9LNm5sd1U2WDFiM280eVhfNXJSd1ZVTGNQRExEN3EwLU1abTVwOVFNN1lSQ3AyRmIwZlpud29yUEs5SFB3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T14:52:00+00:00", "published_display": "15 Jul 2026 14:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity (CELC) Sees a 12.6% Decline in Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQcTJMTDktS3YtZ1JGUXBUVS04dEdwVUpKc0Z5MWJRQlVNamxZTXpOajFMeDJzeHlmRmlhdkFualVFMnAzSVp3dUVhQlZwNnpOU1ByN2JzeWttZ0ExX28tcHNhQ09TbzZPOUxfMDFGS0k4UlBJWmNfZTR2ajJNWU1CTEVxMFlvbk1hdmRpQ2wtYw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T14:50:11+00:00", "published_display": "15 Jul 2026 14:50", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity falls despite FDA nod for breast cancer drug (CELC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxORWp4Z0R6Y1JuYlNpelhoM2JaOU0xN1JwUzVfZWt3X0ttQ3VFZkt0S21KOHRibzZYLVdZNlg4V3lES2pwUTNFRFc2UkxHQnliNmlrS3FZMkZCNndRa1NfRU1QV0RIUWRqdkpCRWlibHpuYU1ZV21HakQ0UkZMNjM0VlBjRVJDV09JMmw0UzJmZlc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T14:17:37+00:00", "published_display": "15 Jul 2026 14:17", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-shares-fall-delayed-breast-124344986.html", "source_name": "Reuters", "published_at": "2026-07-15T13:03:14+00:00", "published_display": "15 Jul 2026 13:03", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel reiterates Celcuity stock rating on FDA approval of Revtorpyk", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxONDV6b284REZBTzVBa3ZUSXZmaDAtZll0LUtYWllFYUxBT1Y5NV8wXzZnSTFWaGZySmtPYlJDSHh2ZVZrQk9SbUNtMlVXSWcyY2ozZ1RndXN0VDBhQy0tc25lWHFHNW00M014RDlGSy1VcFMzQndxTk1GeEJPSGFLQWlOME02RjFXSDI1eTBRa09vQklYaVBaRFM5V3BjSmwzRXRXdUgzZVR1N20tNk1Pd1M2VUJCRi03d0x1Wk5vcVRlYnVvS1BR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T12:16:07+00:00", "published_display": "15 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity wins breast cancer nod, securing \u2018differentiated foothold\u2019 in market", "summary": "Celcuity has received FDA approval for its kinase inhibitor gedatolisib, branded as Revtorpyk, for specific patients with advanced HR-positive, HER2-negative breast cancer without PIK3CA mutations. This approval provides Celcuity with a unique position in the market, distinguishi", "url": "https://www.biospace.com/fda/celcuity-wins-breast-cancer-nod-securing-differentiated-foothold-in-market", "source_name": "BioSpace", "published_at": "2026-07-15T11:41:53", "published_display": "15 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Celcuity(CELC.US) Insider Proposes to Sell 290.96 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNRS12QTlCNEo2SVhJV3FCWlN4bVN0cW5iMXZPcGFGSEFOczNWOXIwTGhtR09LYkl0dVJsREoxNDZZYXFxeWpFZnZNZ3FqMjZZNXhNYmRaVDBGUG5TbmRjX1doNTV2T3RLS1U0TmF1ZDlBRnVfYWRSNzZYRmJEQ0FJOHJzcnF0Sm4tOWJjbHB3WHlJOXlHY0k2UE5ZeTRHdXZi?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T10:21:41+00:00", "published_display": "15 Jul 2026 10:21", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/m/404dd367-4815-3366-8500-30386df4b4a3/celcuity-enters-commercial.html", "source_name": "MarketBeat", "published_at": "2026-07-15T08:02:02+00:00", "published_display": "15 Jul 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity gains FDA approval for closely-watched breast cancer drug", "summary": "Celcuity received FDA approval for its breast cancer drug Revtorpyk, to be used in combination with hormone therapy and Pfizer\u2019s Ibrance for certain advanced ER-positive, HER2-negative patients. Despite this regulatory win, Celcuity's shares fell due to unexpected launch timing a", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-gains-fda-approval-closely-121800691.html", "source_name": "Market source", "published_at": "2026-07-15T07:18:00", "published_display": "15 Jul 2026 07:18", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Announces FDA Approval of REVTORPYK\u2122 (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer", "summary": "Celcuity Inc. announced that the FDA has approved REVTORPYK\u2122 (gedatolisib) for the treatment of HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. This approval is based on positive results from the Phase 3 VIKTORIA-1 trial, which showed significant improve", "url": "https://www.biospace.com/press-releases/celcuity-announces-fda-approval-of-revtorpyk-gedatolisib-for-the-treatment-of-hr-her2-pik3ca-wild-type-locally-advanced-or-metastatic-breast-cancer", "source_name": "BioSpace", "published_at": "2026-07-15T04:10:34", "published_display": "15 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity's REVTORPYK Gets FDA Approval for HR+/HER2- Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-apos-revtorpyk-gets-fda-211941785.html", "source_name": "MT Newswires", "published_at": "2026-07-14T21:19:41+00:00", "published_display": "14 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With FDA approval for its breast cancer blockbuster hopeful, Celcuity could \u2018belong in the hands\u2019 of a Big Pharma", "summary": "Celcuity has received FDA approval for its new small molecule inhibitor, Revtorpyk (gedatolisib), for previously treated hormone receptor-positive, HER2-negative breast cancer patients without PIK3CA mutations. This drug has blockbuster potential and could become a new standard o", "url": "https://www.fiercepharma.com/pharma/fda-approval-its-breast-cancer-blockbuster-hopeful-celcuity-could-belong-hands-big-pharma", "source_name": "Fierce Pharma", "published_at": "2026-07-14T21:56:00", "published_display": "14 Jul 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity's REVTORPYK combination reduced progression-or-death risk 76%", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNdjJtdDFkUXF2MjliX1dSdkxFTGlMalhINWd1RDd6cWRhbFM4WjJ3UFBYLVAtSjlpN01wVkZfWUVGNkVHUVNIVy1mTHZvQW9MRnJ4N3V1WG13NWt2c2pnTkRtNUVnSk5QSmI5cDZfbjlxU3FzMGNORmliOEhpSTBuZkVMTnljakE3Nkk3YVZVd1VPbjdmb2xPZFhPVjJ6LXBUM2JfY1A5TEFVQ0VYUmlJbmlqN3BCMnZXdkNkSHdR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:53:00+00:00", "published_display": "14 Jul 2026 20:53", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug", "summary": "Celcuity Inc. (CELC) shares surged 7% after the FDA approved its cancer drug, gedatolisib, in combination with fulvestrant, with or without Pfizer's palbociclib, for advanced hormone receptor-positive, HER2-negative breast cancer. This marks Celcuity's first marketed product, tra", "url": "https://finance.yahoo.com/healthcare/articles/celc-stock-clocks-best-day-212445145.html", "source_name": "Market source", "published_at": "2026-07-14T21:24:00", "published_display": "14 Jul 2026 21:24", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Announces FDA Approval of REVTORPYK\u2122 (gedatolisib)", "summary": "Celcuity Inc. announced that the FDA approved REVTORPYK\u2122 (gedatolisib) for the treatment of HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation. This approval is based on positive Phase 3 VIKTORIA-1 trial results, showing significant reduction in dise", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327323/0/en/celcuity-announces-fda-approval-of-revtorpyk-gedatolisib-for-the-treatment-of-hr-her2-pik3ca-wild-type-locally-advanced-or-metastatic-breast-cancer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T21:03:39", "published_display": "14 Jul 2026 21:03", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Celcuity\u2019s breast cancer drug", "summary": "The U.S. FDA has approved Celcuity\u2019s drug, Revtorpyk (gedatolisib), for an advanced form of breast cancer, marking the company's first product to gain market entry. This approval is based on late-stage data showing the drug significantly reduced the risk of disease progression or", "url": "https://srnnews.com/us-fda-approves-celcuitys-breast-cancer-drug/", "source_name": "SRN News", "published_at": "2026-07-14T21:03:39", "published_display": "14 Jul 2026 21:03", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC6416934 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides the coupon profile for the CELC6416934 bond issued by Celcuity, Inc. It details the current coupon rate of 0.25% and notes that the next interest payment is scheduled for February 1, 2027. The article encourages users to unlock full data for more in-depth bo", "url": "https://www.tradingview.com/symbols/FINRA-CELC6416934/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-14T07:42:28", "published_display": "14 Jul 2026 07:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Will Celcuity's (CELC) Broad Russell Index Removal Reshape Its Gedatolisib-Centric Investment Narrative", "summary": "Celcuity Inc. (CELC) was removed from several Russell indices, which may impact its visibility and liquidity. This removal does not, however, alter the core investment narrative centered on the prospects of its drug gedatolisib and upcoming regulatory milestones. The article high", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/will-celcuitys-celc-broad-russell-index-removal-reshape-its/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T01:39:12", "published_display": "10 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Rises as Investors Focus on Near-Term FDA Catalyst for Gedatolisib", "summary": "Celcuity's stock rose as investors anticipate a near-term FDA catalyst for its drug candidate, gedatolisib. The company submitted a BTD application for gedatolisib in 2L/3L HR+/HER2- metastatic breast cancer, with a response expected by August 12. Positive outcomes from this regu", "url": "https://www.moomoo.com/news/post/72630496/celcuity-rises-as-investors-focus-on-near-term-fda-catalyst", "source_name": "Moomoo", "published_at": "2026-07-08T13:10:28", "published_display": "08 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC Stock Holds Trend As Opaque Insider Filings Hit Tape", "summary": "Celcuity Inc. (CELC) surged over 6.5% due to positive breast cancer trial results, despite opaque insider filings. Two Form 4 filings indicated changes in beneficial ownership but lacked crucial details like transaction size or direction, making it difficult for traders to assess", "url": "https://stockstotrade.com/news/celcuity-inc-celc-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T20:11:50", "published_display": "07 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Celcuity (CELC) Undervalued After Its Removal From Major Russell Indices?", "summary": "Celcuity (CELC) was recently removed from major Russell indices, which could impact its trading flows. Despite this, the stock has shown strong recent price momentum. The company is currently pre-revenue but analysts forecast significant future revenue and profitability, leading ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/is-celcuity-celc-undervalued-after-its-removal-from-major-ru", "source_name": "Simply Wall Street", "published_at": "2026-07-07T01:11:29", "published_display": "07 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Celcuity Inc. (CELC) Risk Zones", "summary": "This article provides a precision trading analysis for Celcuity Inc. (CELC) using AI models, highlighting strong sentiment across all horizons and an exceptional risk-reward setup. It outlines three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging", "url": "https://news.stocktradersdaily.com/news_release/151/Precision_Trading_with_Celcuity_Inc._CELC_Risk_Zones_070626105602_1783349762.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T10:39:47", "published_display": "06 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC - Celcuity Inc Options", "summary": "This article provides detailed financial data and performance metrics for Celcuity Inc. (CELC). It includes key financial ratios, stock performance over various periods, insider and institutional ownership, and analyst recommendations. The data highlights the company's valuation,", "url": "https://finviz.com/stock?t=CELC&p=d&ty=oc&b=2&r=y1&ov=chain_strike&s=75", "source_name": "Finviz", "published_at": "2026-07-02T12:12:22", "published_display": "02 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Celcuity Inc. \u2013 NASDAQ:CELC", "summary": "This article provides access to the \"Price to earnings forward\" financial metric for Celcuity Inc. (NASDAQ: CELC) on the TradingView platform. It appears to be a stub or a data point within a larger financial analysis tool, showcasing the company's ticker and market. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-CELC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T09:41:13", "published_display": "30 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Celcuity Inc. \u2013 DUS:7VR", "summary": "This article provides the \"Price to sales forward\" metric for Celcuity Inc. (DUS:7VR) on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The page also offers overview information, financials, news, community, techn", "url": "https://www.tradingview.com/symbols/DUS-7VR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:40:55", "published_display": "29 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Inc.(NasdaqCM: CELC) dropped from Russell 2000 Value Benchmark", "summary": "Celcuity Inc. (NasdaqCM: CELC) has been dropped from the Russell 2000 Value Benchmark, as well as the Russell Microcap Value Benchmark Index, Russell 3000E Growth Benchmark, Russell Microcap Index, and Russell 3000E Index. The company is a clinical-stage biotechnology firm develo", "url": "https://www.marketscreener.com/news/celcuity-inc-nasdaqcm-celc-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88bff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:40:55", "published_display": "29 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Celcuity Inc. \u2013 NASDAQ:CELC", "summary": "This article focuses on the enterprise value to revenue forward metric for Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data point presented within a TradingView context, indicating no trades and providing an overview of the company's financial information. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-CELC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:39:41", "published_display": "28 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Celcuity Inc. \u2013 MUN:7VR", "summary": "The article displays the enterprise value to EBITDA forward for Celcuity Inc. (MUN:7VR) on the Munich Stock Exchange. It focuses solely on this financial metric, indicating that the market was closed with no trades at the time of viewing.", "url": "https://www.tradingview.com/symbols/MUN-7VR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:39:41", "published_display": "28 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Celcuity Inc. \u2013 MUN:7VR", "summary": "This article provides financial information for Celcuity Inc. (MUN:7VR) listed on the Munich Stock Exchange, specifically focusing on its enterprise value to forward revenue. It appears to be a financial data snippet from a larger platform, offering an overview of the company's f", "url": "https://www.tradingview.com/symbols/MUN-7VR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:10:35", "published_display": "28 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Celcuity Inc. \u2013 NASDAQ:CELC", "summary": "This article focuses on the enterprise value to EBIT forward of Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data page from TradingView, displaying stock information and financial metrics for the company. The content primarily highlights the \"Enterprise value to EBI", "url": "https://www.tradingview.com/symbols/NASDAQ-CELC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T12:10:35", "published_display": "28 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Celcuity Inc. \u2013 MUN:7VR", "summary": "This article presents the \"Price to book forward\" financial metric for Celcuity Inc. (MUN:7VR), indicating its value and change over a period. It highlights that the information is 'Made by humans' and uses market data from ICE Data Services and reference data from FactSet.", "url": "https://www.tradingview.com/symbols/MUN-7VR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:09:49", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Inc. Actuals & Estimates (HAM:7VR)", "summary": "This article provides an overview of Celcuity Inc. (7VR) stock performance, analyst estimates, and financial data on the Hamburg Stock Exchange. It includes details on the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along ", "url": "https://www.tradingview.com/symbols/HAM-7VR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:09:37", "published_display": "26 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celcuity-celc-weighs-dilution-against-191120548.html", "source_name": "Simply Wall St.", "published_at": "2026-06-04T19:11:20+00:00", "published_display": "04 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Prices $500 Million Convertible Notes Due 2032", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/celcuity-prices-500-million-convertible-121201799.html", "source_name": "MT Newswires", "published_at": "2026-06-04T12:12:01+00:00", "published_display": "04 Jun 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Celcuity stock sliding today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNcmhCNjZZeDVuUHdZSFVQczEtLVZNRjEyWDJjeDAybnRINURDcmpOV1VBUFFZektFbXdfekp6WDJHOGdZUkhYNUpwejJ4WnNyYjhZRldJSmI5ZDZETm9tVTRpbkV6TGtWZ1RpNUZWNUZOemw2SnNLanp3Q2hzRmFwUkFweTEzdUVEaU13cXFuMTc4X2JXdnhHb0ZuVnFkQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Celcuity stock plunging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQVGd0MDdfZDczNG8tcUhOU3QxbENhTnVBZzZKVk03STQxUHhmVlpDUF9CRUhPY3h3NWxYemJsdnlla2xjN0tnWDUybjVMVjBreXV6cTRBbkZoSUJ6LVMzRXhiTTVKZ2MwZHBHRHNnN2tOejd6ZWM4UzBCU3hTbEotM1JGN3N5c0RaQkhZdEVwN2dnS3JiUlcxZlE1OTcxakU?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPZkVaY3p2Q2VVcUxPOTl5VS1SS3NKWG1USlVqR1J6ZG1kQTJGVWRRQkp5Nkh4TEQyRnBTeDMzZkxWNmtETEVMVkFLLXljdXlnOUNPNm0zVVUwbmw0TTJyNXlMT1F5QmhLVnNCSEM5aXlxMXU2SGlROFk5YW1BVFl1RkRzb0REVU9aWVR1TkNtMlVoWUM5eE1JRG03bGFRSXhGRjV4UXM2RQ?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Celcuity expands phase 3 breast cancer trial design", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVHp5UGhIN0lIY2lIcnZLMDRtVnRrbk1aTTlIbkdJZ3NNRWU3Zk5jbjJ5SEJjNHNycGxBYmxtZnZzMTFzZlZEQ25rZXFqU0ZfNmpQOGFnenNaVWdPdlljZU4xaGdxa2VWd21jcEdXeVJ3X0JDTlJCZER3eWYxejNzN0ZlcG16ZjF3TlJsMXo2a0VKVHBrU050SFpBNFY1Q1BPeUUwVE9lT1FBd0hv?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity earnings up next as FDA approval decision looms", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNYnJsRGR3LUY3NENtbGNZTHpzTUdkTWFNZGJmOEthMmczb1FqMWt0SmRnTUx6REd6TWlmamFRRnJ4VTlDZG1iYUFnQ1lDMDlwcWJ4Z19sZWxLdEZ4UXhJUVJWRkdVdERMRjdScU05eVlaWndVeXgwQkt0UFhrUTdMLVF3SFdsWmhKSGczNl8tdGttRjZQcC12V3M4SVBoLUFySTlva1VoanRTbWVRRlE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNa2hIcGhaQkhKLWgxVGxnWWp6TWhSbzFqVTRvbnpuQ2M4dGtxQWhyLXJCb2g4cXM3el9PeUhINFJ1SmR4akpHQVF1NHJRalFLOW1JeUloZFNtWEYxUXh3RGlsdnA3WVFWTlYtcWdWQmVPMUU0ajhjOUZ4b3ItWUhHVENXVVFlOVEzbnBOMDB5dXBxUXQ5NjR4eUFEYw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOdjREMDlIalVNMS02T0pEVl9DWkJSNmZobjlGV2s4dGRGOFgtRmFlRC1kVWJJZGp4NmJOMU9yMjlFWFpjOWtUVkFMcU03cTZQcUE3cjRScDh6N2VDdFRsNUt2c2M5RTNXdFNZSjRsWmF6a1VUZXh1VXlXc0I0MjRxLXRKVmUwYW5TQXc2Z0ExSHFZWk1OWXpLbWRvaG12dF96T3c?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPT09ScjJOelFNWnl3V203STNFYnEwLW5tb082SmhvSjdGVGFEbndZankzZS04TlBJSW5GTkZFcmxsdG9qQTE2VGNqVE1EdzhVSVItSzZFcWdaQmhVLS1ES3BrTXEzajVoanBlc0JVMW1iaERmZTdtd0xXRzdDNTZ0Y3lnaGFfRDBnM2hXNExOVUt3cFBDWWp0QWhWZklfams1LUJjOQ?oc=5", "source_name": "Market source", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "by_tier": {"direct": [{"title": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC", "summary": "Pomerantz LLP is investigating potential securities fraud claims against Celcuity Inc. (NASDAQ: CELC) on behalf of investors. The investigation follows a significant drop in Celcuity's stock price after the company announced U.S. Food and Drug Administration approval for its brea", "url": "https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-celcuity-inc---celc-302828050.html", "source_name": "PR Newswire", "published_at": "2026-07-16T23:40:05", "published_display": "16 Jul 2026 23:40", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Baker Bros. Advisors LP sells $317.75m Celcuity shares at $102.50", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxPa0FVQmRoemh4cU9wNlpwZEhMbUx6YnVVaGZ5eGRsVG10TEtNM1o2Q1UyWElxTjhxelBPU01tOWcwRHZ1QmNjclI2bG0xSnhXajNFUWJ2ODVYb3ZCTGtRc0h6U2cyU1pyZUNHSzJQbEhjZTZfWXFKdlZja3FKdVJmT19jcXdEWVhvNHduVWhqNkhTU3JSOFJDM0NwdXZSVllzeFpHVVk5VHBCczRDVEdCaFNJdVpoRldxWl9RT0tDZTQ1dVk?oc=5", "source_name": "Investing.com", "published_at": "2026-07-16T22:27:29+00:00", "published_display": "16 Jul 2026 22:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Celcuity LLC For: 16 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxORFE4TmJrY01XZ2g5QmMyRlJEZ0o1anNyMGdTb053LTVSMDcyc3VSRl9LT0h3YnptRWYxZFNkQUJOSzhQOTYwMUxWR0pPek9QZzFaQXdYeV9sa2MyMnZFZVFtRmhaaFFZWmJ0M2hQcmdVWjNoejhmT09EUFotMHdKYVF5Mjg5eEJGc3F4aEFfUUdnaXJTTG5N?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-16T21:52:15+00:00", "published_display": "16 Jul 2026 21:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $155 to $178", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPbU42UFNoR1JnWXRYVFdpUzZ2N3VBdktlS25iMVNOX3ItalpsZ2dDUXZIaWd1UVJzVElyT3NoRW1WYnRnUUJ5T0gwWTNwWS1VZE0wMjJwSFVlLXFlNy1yTmhNVlVKNFFTcG1velBvU1prc0ZnVm5TOUxBYnkzajNzbmlMdDlCYmltazFTUjllTFVXUlVTWXhNVA?oc=5", "source_name": "Moomoo", "published_at": "2026-07-16T13:08:27+00:00", "published_display": "16 Jul 2026 13:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations", "summary": "Celcuity Inc. secured early FDA approval for REVTORPYK (gedatolisib) for HR+/HER2- breast cancer, signaling a potential multi-billion dollar market opportunity. The drug, a first-in-class pan-PI3K/mTOR inhibitor, demonstrated superior efficacy and a favorable safety profile compa", "url": "https://www.kavout.com/market-lens/celcuity-s-revtorpyk-approval-a-multi-billion-dollar-breakthrough-despite-high-expectations", "source_name": "Kavout | AI", "published_at": "2026-07-16T10:13:17", "published_display": "16 Jul 2026 10:13", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity (CELC) Experiences Significant Decline", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxNcFB1ZnJvQk1zTml6cGt1d0RFYTJzZmRzcjJ3QTcyYmRNR1ZZanJkNmV4dkJEZ2N3VXRHYzNTMTlXcmRZMFhHWElqdFZJY1FidV8ydUktZWlUaDhjWTY0MjV6VlBMWmxqR1RqenYwRnZReXlqWWZiR05XY3NNYkY4ZWZCMEJ3QTd6SjVLMW1DVHZDdDNKYllMYWo3ZE9DZGNhS09DNnhLTG12OGZ6OVdJc2pDUWUtZmhsZk1RYXo2bnJlQQ?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T03:02:52+00:00", "published_display": "16 Jul 2026 03:02", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026 (CELC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxOc0xTNFZKbTN1Uzlab3l0MmJIZ2diWE1pUWRNZ1ZJT1VGWUd3MG1tRFFYOE1leHhzUG1ZbUFPNy1pVnhpOE0yN0RmTElKNnVkNWlNR2w4bEtuLWxERnB6em1tV2dnRXJlMFlMTTktYi1lSkk2VlJYNWFHX1FFdHJmam1oMzVkRC1pcW1IVUx5WkdmZDlod21aMi1zWmlobDhrbFJIOERCOUo4U0tIR0hSOGpfQU1EZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T17:45:24+00:00", "published_display": "15 Jul 2026 17:45", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity gains FDA approval for closely watched breast cancer drug", "summary": "Celcuity received FDA approval for its breast cancer drug, Revtorpyk, for use in specific combinations for advanced ER-positive, HER2-negative breast cancer patients without a PIK3CA mutation. Despite the approval, Celcuity's shares fell by nearly 20% due to a delayed launch time", "url": "https://www.biopharmadive.com/news/celcuity-fda-approve-revtorpyk-breast-cancer/825280/", "source_name": "BioPharma Dive", "published_at": "2026-07-15T16:10:35", "published_display": "15 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity\u2019s Revtorpyk wins FDA nod in breast cancer", "summary": "Celcuity Inc. received FDA approval for Revtorpyk (gedatolisib) for a subset of breast cancer patients, marking the company's first commercial product and a new treatment option. Despite this positive news, investor excitement was dampened by an unanticipated launch delay, causin", "url": "https://www.bioworld.com/articles/732608-celcuitys-revtorpyk-wins-fda-nod-in-breast-cancer", "source_name": "BioWorld News", "published_at": "2026-07-15T16:10:35", "published_display": "15 Jul 2026 16:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Slides as Investors Appear to Take Profits After FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbU9KM0FHTWx4SE5JWmtzTkZHa29vbDZKLXQ3SUFyWTVRLVZwZGhKaERqeVE1MXhtSVpIRkRtZ25xaEd6ZVVPNlhRbDNaRkgtOFJKTnNLOEY3dzhjelBiR0NtWXpsbGpaUW9LNm5sd1U2WDFiM280eVhfNXJSd1ZVTGNQRExEN3EwLU1abTVwOVFNN1lSQ3AyRmIwZlpud29yUEs5SFB3?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-07-15T14:52:00+00:00", "published_display": "15 Jul 2026 14:52", "sentiment": "positive", "sentiment_pct": 66, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity (CELC) Sees a 12.6% Decline in Stock Price", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQcTJMTDktS3YtZ1JGUXBUVS04dEdwVUpKc0Z5MWJRQlVNamxZTXpOajFMeDJzeHlmRmlhdkFualVFMnAzSVp3dUVhQlZwNnpOU1ByN2JzeWttZ0ExX28tcHNhQ09TbzZPOUxfMDFGS0k4UlBJWmNfZTR2ajJNWU1CTEVxMFlvbk1hdmRpQ2wtYw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T14:50:11+00:00", "published_display": "15 Jul 2026 14:50", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity falls despite FDA nod for breast cancer drug (CELC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxORWp4Z0R6Y1JuYlNpelhoM2JaOU0xN1JwUzVfZWt3X0ttQ3VFZkt0S21KOHRibzZYLVdZNlg4V3lES2pwUTNFRFc2UkxHQnliNmlrS3FZMkZCNndRa1NfRU1QV0RIUWRqdkpCRWlibHpuYU1ZV21HakQ0UkZMNjM0VlBjRVJDV09JMmw0UzJmZlc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-15T14:17:37+00:00", "published_display": "15 Jul 2026 14:17", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-shares-fall-delayed-breast-124344986.html", "source_name": "Reuters", "published_at": "2026-07-15T13:03:14+00:00", "published_display": "15 Jul 2026 13:03", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stifel reiterates Celcuity stock rating on FDA approval of Revtorpyk", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxONDV6b284REZBTzVBa3ZUSXZmaDAtZll0LUtYWllFYUxBT1Y5NV8wXzZnSTFWaGZySmtPYlJDSHh2ZVZrQk9SbUNtMlVXSWcyY2ozZ1RndXN0VDBhQy0tc25lWHFHNW00M014RDlGSy1VcFMzQndxTk1GeEJPSGFLQWlOME02RjFXSDI1eTBRa09vQklYaVBaRFM5V3BjSmwzRXRXdUgzZVR1N20tNk1Pd1M2VUJCRi03d0x1Wk5vcVRlYnVvS1BR?oc=5", "source_name": "Investing.com", "published_at": "2026-07-15T12:16:07+00:00", "published_display": "15 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity wins breast cancer nod, securing \u2018differentiated foothold\u2019 in market", "summary": "Celcuity has received FDA approval for its kinase inhibitor gedatolisib, branded as Revtorpyk, for specific patients with advanced HR-positive, HER2-negative breast cancer without PIK3CA mutations. This approval provides Celcuity with a unique position in the market, distinguishi", "url": "https://www.biospace.com/fda/celcuity-wins-breast-cancer-nod-securing-differentiated-foothold-in-market", "source_name": "BioSpace", "published_at": "2026-07-15T11:41:53", "published_display": "15 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 | Celcuity(CELC.US) Insider Proposes to Sell 290.96 Million in Common Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNRS12QTlCNEo2SVhJV3FCWlN4bVN0cW5iMXZPcGFGSEFOczNWOXIwTGhtR09LYkl0dVJsREoxNDZZYXFxeWpFZnZNZ3FqMjZZNXhNYmRaVDBGUG5TbmRjX1doNTV2T3RLS1U0TmF1ZDlBRnVfYWRSNzZYRmJEQ0FJOHJzcnF0Sm4tOWJjbHB3WHlJOXlHY0k2UE5ZeTRHdXZi?oc=5", "source_name": "Moomoo", "published_at": "2026-07-15T10:21:41+00:00", "published_display": "15 Jul 2026 10:21", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Enters Commercial Stage as FDA Approves REVTORPYK for Advanced Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/m/404dd367-4815-3366-8500-30386df4b4a3/celcuity-enters-commercial.html", "source_name": "MarketBeat", "published_at": "2026-07-15T08:02:02+00:00", "published_display": "15 Jul 2026 08:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity gains FDA approval for closely-watched breast cancer drug", "summary": "Celcuity received FDA approval for its breast cancer drug Revtorpyk, to be used in combination with hormone therapy and Pfizer\u2019s Ibrance for certain advanced ER-positive, HER2-negative patients. Despite this regulatory win, Celcuity's shares fell due to unexpected launch timing a", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-gains-fda-approval-closely-121800691.html", "source_name": "Market source", "published_at": "2026-07-15T07:18:00", "published_display": "15 Jul 2026 07:18", "sentiment": "positive", "sentiment_pct": 61, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Announces FDA Approval of REVTORPYK\u2122 (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer", "summary": "Celcuity Inc. announced that the FDA has approved REVTORPYK\u2122 (gedatolisib) for the treatment of HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. This approval is based on positive results from the Phase 3 VIKTORIA-1 trial, which showed significant improve", "url": "https://www.biospace.com/press-releases/celcuity-announces-fda-approval-of-revtorpyk-gedatolisib-for-the-treatment-of-hr-her2-pik3ca-wild-type-locally-advanced-or-metastatic-breast-cancer", "source_name": "BioSpace", "published_at": "2026-07-15T04:10:34", "published_display": "15 Jul 2026 04:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity's REVTORPYK Gets FDA Approval for HR+/HER2- Breast Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/celcuity-apos-revtorpyk-gets-fda-211941785.html", "source_name": "MT Newswires", "published_at": "2026-07-14T21:19:41+00:00", "published_display": "14 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With FDA approval for its breast cancer blockbuster hopeful, Celcuity could \u2018belong in the hands\u2019 of a Big Pharma", "summary": "Celcuity has received FDA approval for its new small molecule inhibitor, Revtorpyk (gedatolisib), for previously treated hormone receptor-positive, HER2-negative breast cancer patients without PIK3CA mutations. This drug has blockbuster potential and could become a new standard o", "url": "https://www.fiercepharma.com/pharma/fda-approval-its-breast-cancer-blockbuster-hopeful-celcuity-could-belong-hands-big-pharma", "source_name": "Fierce Pharma", "published_at": "2026-07-14T21:56:00", "published_display": "14 Jul 2026 21:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity's REVTORPYK combination reduced progression-or-death risk 76%", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNdjJtdDFkUXF2MjliX1dSdkxFTGlMalhINWd1RDd6cWRhbFM4WjJ3UFBYLVAtSjlpN01wVkZfWUVGNkVHUVNIVy1mTHZvQW9MRnJ4N3V1WG13NWt2c2pnTkRtNUVnSk5QSmI5cDZfbjlxU3FzMGNORmliOEhpSTBuZkVMTnljakE3Nkk3YVZVd1VPbjdmb2xPZFhPVjJ6LXBUM2JfY1A5TEFVQ0VYUmlJbmlqN3BCMnZXdkNkSHdR?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-14T20:53:00+00:00", "published_display": "14 Jul 2026 20:53", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug", "summary": "Celcuity Inc. (CELC) shares surged 7% after the FDA approved its cancer drug, gedatolisib, in combination with fulvestrant, with or without Pfizer's palbociclib, for advanced hormone receptor-positive, HER2-negative breast cancer. This marks Celcuity's first marketed product, tra", "url": "https://finance.yahoo.com/healthcare/articles/celc-stock-clocks-best-day-212445145.html", "source_name": "Market source", "published_at": "2026-07-14T21:24:00", "published_display": "14 Jul 2026 21:24", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Announces FDA Approval of REVTORPYK\u2122 (gedatolisib)", "summary": "Celcuity Inc. announced that the FDA approved REVTORPYK\u2122 (gedatolisib) for the treatment of HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation. This approval is based on positive Phase 3 VIKTORIA-1 trial results, showing significant reduction in dise", "url": "https://www.globenewswire.com/news-release/2026/07/14/3327323/0/en/celcuity-announces-fda-approval-of-revtorpyk-gedatolisib-for-the-treatment-of-hr-her2-pik3ca-wild-type-locally-advanced-or-metastatic-breast-cancer.html", "source_name": "GlobeNewswire", "published_at": "2026-07-14T21:03:39", "published_display": "14 Jul 2026 21:03", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA approves Celcuity\u2019s breast cancer drug", "summary": "The U.S. FDA has approved Celcuity\u2019s drug, Revtorpyk (gedatolisib), for an advanced form of breast cancer, marking the company's first product to gain market entry. This approval is based on late-stage data showing the drug significantly reduced the risk of disease progression or", "url": "https://srnnews.com/us-fda-approves-celcuitys-breast-cancer-drug/", "source_name": "SRN News", "published_at": "2026-07-14T21:03:39", "published_display": "14 Jul 2026 21:03", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC6416934 Bond Coupon Profile \u2014 Rate & Payments", "summary": "This article provides the coupon profile for the CELC6416934 bond issued by Celcuity, Inc. It details the current coupon rate of 0.25% and notes that the next interest payment is scheduled for February 1, 2027. The article encourages users to unlock full data for more in-depth bo", "url": "https://www.tradingview.com/symbols/FINRA-CELC6416934/profile-coupon/", "source_name": "TradingView", "published_at": "2026-07-14T07:42:28", "published_display": "14 Jul 2026 07:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Celcuity's (CELC) Broad Russell Index Removal Reshape Its Gedatolisib-Centric Investment Narrative", "summary": "Celcuity Inc. (CELC) was removed from several Russell indices, which may impact its visibility and liquidity. This removal does not, however, alter the core investment narrative centered on the prospects of its drug gedatolisib and upcoming regulatory milestones. The article high", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/will-celcuitys-celc-broad-russell-index-removal-reshape-its/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-10T01:39:12", "published_display": "10 Jul 2026 01:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Rises as Investors Focus on Near-Term FDA Catalyst for Gedatolisib", "summary": "Celcuity's stock rose as investors anticipate a near-term FDA catalyst for its drug candidate, gedatolisib. The company submitted a BTD application for gedatolisib in 2L/3L HR+/HER2- metastatic breast cancer, with a response expected by August 12. Positive outcomes from this regu", "url": "https://www.moomoo.com/news/post/72630496/celcuity-rises-as-investors-focus-on-near-term-fda-catalyst", "source_name": "Moomoo", "published_at": "2026-07-08T13:10:28", "published_display": "08 Jul 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC Stock Holds Trend As Opaque Insider Filings Hit Tape", "summary": "Celcuity Inc. (CELC) surged over 6.5% due to positive breast cancer trial results, despite opaque insider filings. Two Form 4 filings indicated changes in beneficial ownership but lacked crucial details like transaction size or direction, making it difficult for traders to assess", "url": "https://stockstotrade.com/news/celcuity-inc-celc-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T20:11:50", "published_display": "07 Jul 2026 20:11", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Celcuity (CELC) Undervalued After Its Removal From Major Russell Indices?", "summary": "Celcuity (CELC) was recently removed from major Russell indices, which could impact its trading flows. Despite this, the stock has shown strong recent price momentum. The company is currently pre-revenue but analysts forecast significant future revenue and profitability, leading ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-celc/celcuity/news/is-celcuity-celc-undervalued-after-its-removal-from-major-ru", "source_name": "Simply Wall Street", "published_at": "2026-07-07T01:11:29", "published_display": "07 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Celcuity Inc. (CELC) Risk Zones", "summary": "This article provides a precision trading analysis for Celcuity Inc. (CELC) using AI models, highlighting strong sentiment across all horizons and an exceptional risk-reward setup. It outlines three distinct trading strategies\u2014Position Trading, Momentum Breakout, and Risk Hedging", "url": "https://news.stocktradersdaily.com/news_release/151/Precision_Trading_with_Celcuity_Inc._CELC_Risk_Zones_070626105602_1783349762.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-06T10:39:47", "published_display": "06 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CELC - Celcuity Inc Options", "summary": "This article provides detailed financial data and performance metrics for Celcuity Inc. (CELC). It includes key financial ratios, stock performance over various periods, insider and institutional ownership, and analyst recommendations. The data highlights the company's valuation,", "url": "https://finviz.com/stock?t=CELC&p=d&ty=oc&b=2&r=y1&ov=chain_strike&s=75", "source_name": "Finviz", "published_at": "2026-07-02T12:12:22", "published_display": "02 Jul 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Celcuity Inc. \u2013 NASDAQ:CELC", "summary": "This article provides access to the \"Price to earnings forward\" financial metric for Celcuity Inc. (NASDAQ: CELC) on the TradingView platform. It appears to be a stub or a data point within a larger financial analysis tool, showcasing the company's ticker and market. The content ", "url": "https://www.tradingview.com/symbols/NASDAQ-CELC/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T09:41:13", "published_display": "30 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Celcuity Inc. \u2013 DUS:7VR", "summary": "This article provides the \"Price to sales forward\" metric for Celcuity Inc. (DUS:7VR) on the Dusseldorf Stock Exchange. It indicates that the market was closed with no trades at the time of publication. The page also offers overview information, financials, news, community, techn", "url": "https://www.tradingview.com/symbols/DUS-7VR/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:40:55", "published_display": "29 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Inc.(NasdaqCM: CELC) dropped from Russell 2000 Value Benchmark", "summary": "Celcuity Inc. (NasdaqCM: CELC) has been dropped from the Russell 2000 Value Benchmark, as well as the Russell Microcap Value Benchmark Index, Russell 3000E Growth Benchmark, Russell Microcap Index, and Russell 3000E Index. The company is a clinical-stage biotechnology firm develo", "url": "https://www.marketscreener.com/news/celcuity-inc-nasdaqcm-celc-dropped-from-russell-2000-value-benchmark-ce7f5fdfd88bff27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:40:55", "published_display": "29 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Celcuity Inc. \u2013 NASDAQ:CELC", "summary": "This article focuses on the enterprise value to revenue forward metric for Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data point presented within a TradingView context, indicating no trades and providing an overview of the company's financial information. The cont", "url": "https://www.tradingview.com/symbols/NASDAQ-CELC/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T23:39:41", "published_display": "28 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Celcuity Inc. \u2013 MUN:7VR", "summary": "The article displays the enterprise value to EBITDA forward for Celcuity Inc. (MUN:7VR) on the Munich Stock Exchange. It focuses solely on this financial metric, indicating that the market was closed with no trades at the time of viewing.", "url": "https://www.tradingview.com/symbols/MUN-7VR/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:39:41", "published_display": "28 Jun 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Celcuity Inc. \u2013 MUN:7VR", "summary": "This article provides financial information for Celcuity Inc. (MUN:7VR) listed on the Munich Stock Exchange, specifically focusing on its enterprise value to forward revenue. It appears to be a financial data snippet from a larger platform, offering an overview of the company's f", "url": "https://www.tradingview.com/symbols/MUN-7VR/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T18:10:35", "published_display": "28 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Celcuity Inc. \u2013 NASDAQ:CELC", "summary": "This article focuses on the enterprise value to EBIT forward of Celcuity Inc. (NASDAQ: CELC). It appears to be a financial data page from TradingView, displaying stock information and financial metrics for the company. The content primarily highlights the \"Enterprise value to EBI", "url": "https://www.tradingview.com/symbols/NASDAQ-CELC/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T12:10:35", "published_display": "28 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Celcuity Inc. \u2013 MUN:7VR", "summary": "This article presents the \"Price to book forward\" financial metric for Celcuity Inc. (MUN:7VR), indicating its value and change over a period. It highlights that the information is 'Made by humans' and uses market data from ICE Data Services and reference data from FactSet.", "url": "https://www.tradingview.com/symbols/MUN-7VR/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T04:09:49", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Inc. Actuals & Estimates (HAM:7VR)", "summary": "This article provides an overview of Celcuity Inc. (7VR) stock performance, analyst estimates, and financial data on the Hamburg Stock Exchange. It includes details on the current stock price, historical highs and lows, market capitalization, and upcoming earnings reports, along ", "url": "https://www.tradingview.com/symbols/HAM-7VR/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T00:09:37", "published_display": "26 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity (CELC) Weighs Dilution Against Drug Development After $500 Million Convertible Note Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/celcuity-celc-weighs-dilution-against-191120548.html", "source_name": "Simply Wall St.", "published_at": "2026-06-04T19:11:20+00:00", "published_display": "04 Jun 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Prices $500 Million Convertible Notes Due 2032", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/celcuity-prices-500-million-convertible-121201799.html", "source_name": "MT Newswires", "published_at": "2026-06-04T12:12:01+00:00", "published_display": "04 Jun 2026 12:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Celcuity stock sliding today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNcmhCNjZZeDVuUHdZSFVQczEtLVZNRjEyWDJjeDAybnRINURDcmpOV1VBUFFZektFbXdfekp6WDJHOGdZUkhYNUpwejJ4WnNyYjhZRldJSmI5ZDZETm9tVTRpbkV6TGtWZ1RpNUZWNUZOemw2SnNLanp3Q2hzRmFwUkFweTEzdUVEaU13cXFuMTc4X2JXdnhHb0ZuVnFkQQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Celcuity stock plunging today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQVGd0MDdfZDczNG8tcUhOU3QxbENhTnVBZzZKVk03STQxUHhmVlpDUF9CRUhPY3h3NWxYemJsdnlla2xjN0tnWDUybjVMVjBreXV6cTRBbkZoSUJ6LVMzRXhiTTVKZ2MwZHBHRHNnN2tOejd6ZWM4UzBCU3hTbEotM1JGN3N5c0RaQkhZdEVwN2dnS3JiUlcxZlE1OTcxakU?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Shares Fall Despite Strong Phase 3 Breast Cancer Trial Data (CELC)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPZkVaY3p2Q2VVcUxPOTl5VS1SS3NKWG1USlVqR1J6ZG1kQTJGVWRRQkp5Nkh4TEQyRnBTeDMzZkxWNmtETEVMVkFLLXljdXlnOUNPNm0zVVUwbmw0TTJyNXlMT1F5QmhLVnNCSEM5aXlxMXU2SGlROFk5YW1BVFl1RkRzb0REVU9aWVR1TkNtMlVoWUM5eE1JRG03bGFRSXhGRjV4UXM2RQ?oc=5", "source_name": "Market source", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity expands phase 3 breast cancer trial design", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxQVHp5UGhIN0lIY2lIcnZLMDRtVnRrbk1aTTlIbkdJZ3NNRWU3Zk5jbjJ5SEJjNHNycGxBYmxtZnZzMTFzZlZEQ25rZXFqU0ZfNmpQOGFnenNaVWdPdlljZU4xaGdxa2VWd21jcEdXeVJ3X0JDTlJCZER3eWYxejNzN0ZlcG16ZjF3TlJsMXo2a0VKVHBrU050SFpBNFY1Q1BPeUUwVE9lT1FBd0hv?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity earnings up next as FDA approval decision looms", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNYnJsRGR3LUY3NENtbGNZTHpzTUdkTWFNZGJmOEthMmczb1FqMWt0SmRnTUx6REd6TWlmamFRRnJ4VTlDZG1iYUFnQ1lDMDlwcWJ4Z19sZWxLdEZ4UXhJUVJWRkdVdERMRjdScU05eVlaWndVeXgwQkt0UFhrUTdMLVF3SFdsWmhKSGczNl8tdGttRjZQcC12V3M4SVBoLUFySTlva1VoanRTbWVRRlE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Celcuity (CELC) After A 13x One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNa2hIcGhaQkhKLWgxVGxnWWp6TWhSbzFqVTRvbnpuQ2M4dGtxQWhyLXJCb2g4cXM3el9PeUhINFJ1SmR4akpHQVF1NHJRalFLOW1JeUloZFNtWEYxUXh3RGlsdnA3WVFWTlYtcWdWQmVPMUU0ajhjOUZ4b3ItWUhHVENXVVFlOVEzbnBOMDB5dXBxUXQ5NjR4eUFEYw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Celcuity Inc. (CELC): Likely Leader in Next Generation of Breast Cancer Treatments", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOdjREMDlIalVNMS02T0pEVl9DWkJSNmZobjlGV2s4dGRGOFgtRmFlRC1kVWJJZGp4NmJOMU9yMjlFWFpjOWtUVkFMcU03cTZQcUE3cjRScDh6N2VDdFRsNUt2c2M5RTNXdFNZSjRsWmF6a1VUZXh1VXlXc0I0MjRxLXRKVmUwYW5TQXc2Z0ExSHFZWk1OWXpLbWRvaG12dF96T3c?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Celcuity (CELC) Still Attractive After Its Strong One Year Share Price Rally", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPT09ScjJOelFNWnl3V203STNFYnEwLW5tb082SmhvSjdGVGFEbndZankzZS04TlBJSW5GTkZFcmxsdG9qQTE2VGNqVE1EdzhVSVItSzZFcWdaQmhVLS1ES3BrTXEzajVoanBlc0JVMW1iaERmZTdtd0xXRzdDNTZ0Y3lnaGFfRDBnM2hXNExOVUt3cFBDWWp0QWhWZklfams1LUJjOQ?oc=5", "source_name": "Market source", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMigAJBVV95cUxPV1hqSFhQM3VfYlNsdldfeVQ1dEdNNzI3S1RTaFJNSThrOXlPSWpMTlR5WWVxNnNsTzhTVGVvTE94R18wa1A0OUdFczBlcTIzeUFBZUt6VVJJMjNqNks3dmRUSzB4cE40anpNekJwUXAwcTFEcVh4QVZCYURXY2w4b2thdk5KZ3ZJMnI1REJObXo5UDdISXVCU1Z2ZVZoVmJpbnEzaDVWVmpGQVNFZzRXYnp0SWRRWWZGSnZnWlJ4aEloNmJBNGRMVFRjb3ZRbmV3QXF5S0pvTV9xNnpaMWV1Z1ZtM3lPdV9RcEdURHlfZFphdjlicEJndW0ybHNBa205?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-13T03:32:00+00:00", "published_display": "13 Jul 2026 03:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 60, "sentiment_summary": {"positive": 17, "negative": 12, "neutral": 31, "score": 53, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 14.1, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 8.4, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 12}, "market_context": {"has_market_context": true, "latest_close": 107.58, "latest_week": "2026-07-10", "one_week_move": -0.3, "four_week_move": 21.5, "twelve_week_move": -12.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.13669, "market_dynamics_buy_signal": false, "relative_strength": 3.888169, "fair_value_gap": 175.5, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 53.2815, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.3% over one week, +21.5% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 50, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 11}, {"label": "TradingView", "count": 10}, {"label": "Investing.com", "count": 6}, {"label": "Moomoo", "count": 3}, {"label": "GuruFocus", "count": 2}, {"label": "Seeking Alpha", "count": 2}, {"label": "BioSpace", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 14}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.3% over one week, +21.5% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC"}], "updated_at": "2026-07-17T05:44:58.482228+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}